Pfiz­er hits the brakes on their piv­otal tri­al for a BC­MA/CD3 bis­pe­cif­ic on safe­ty con­cerns while FDA road­block is hold­ing up Duchenne MD PhI­II

Pfiz­er’s am­bi­tious plan to take a Phase II study of its BC­MA CD3-tar­get­ed bis­pe­cif­ic an­ti­body el­ranatam­ab (PF-06863135) and run it through to an ac­cel­er­at­ed ap­proval …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER